Titre : Oxystérols

Oxystérols : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Oxystérols : Questions médicales les plus fréquentes", "headline": "Oxystérols : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Oxystérols : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-17", "dateModified": "2025-04-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Oxystérols" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cholestérol", "url": "https://questionsmedicales.fr/mesh/D002784", "about": { "@type": "MedicalCondition", "name": "Cholestérol", "code": { "@type": "MedicalCode", "code": "D002784", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.938.208" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hydroxycholestérols", "alternateName": "Hydroxycholesterols", "url": "https://questionsmedicales.fr/mesh/D006888", "about": { "@type": "MedicalCondition", "name": "Hydroxycholestérols", "code": { "@type": "MedicalCode", "code": "D006888", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.938.208.825.500" } } }, { "@type": "MedicalWebPage", "name": "Cétocholestérols", "alternateName": "Ketocholesterols", "url": "https://questionsmedicales.fr/mesh/D007653", "about": { "@type": "MedicalCondition", "name": "Cétocholestérols", "code": { "@type": "MedicalCode", "code": "D007653", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.938.208.825.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Oxystérols", "alternateName": "Oxysterols", "code": { "@type": "MedicalCode", "code": "D000072376", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yuqin Wang", "url": "https://questionsmedicales.fr/author/Yuqin%20Wang", "affiliation": { "@type": "Organization", "name": "Swansea University Medical School, ILS1 Building, Singleton Park, Swansea SA2 8PP, UK. y.wang@swansea.ac.uk." } }, { "@type": "Person", "name": "William J Griffiths", "url": "https://questionsmedicales.fr/author/William%20J%20Griffiths", "affiliation": { "@type": "Organization", "name": "Swansea University Medical School, ILS1 Building, Singleton Park, Swansea SA2 8PP, UK. w.j.griffiths@swansea.ac.uk." } }, { "@type": "Person", "name": "Caroline Pot", "url": "https://questionsmedicales.fr/author/Caroline%20Pot", "affiliation": { "@type": "Organization", "name": "Laboratories of Neuroimmunology, Neuroscience Research Center and Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and Lausanne University, Chemin des Boveresses 155, 1066 Epalinges, Switzerland. Caroline.Pot-Kreis@chuv.ch." } }, { "@type": "Person", "name": "Gérard Lizard", "url": "https://questionsmedicales.fr/author/G%C3%A9rard%20Lizard", "affiliation": { "@type": "Organization", "name": "Team \"Biochemistry of the Peroxisome, Inflammation and Lipid Metabolism\" EA 7270/Inserm, University Bourgogne Franche-Comté, Dijon, France." } }, { "@type": "Person", "name": "Eylan Yutuc", "url": "https://questionsmedicales.fr/author/Eylan%20Yutuc", "affiliation": { "@type": "Organization", "name": "Swansea University Medical School, ILS1 Building, Singleton Park, Swansea SA2 8PP, UK. eylan.yutuc@swansea.ac.uk." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.", "datePublished": "2023-04-29", "url": "https://questionsmedicales.fr/article/37120458", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10549-023-06943-x" } }, { "@type": "ScholarlyArticle", "name": "Influence of adverse effects of neoadjuvant chemoradiotherapy on the prognosis of patients with early-stage esophageal cancer (cT1b-cT2N0M0) based on the SEER database.", "datePublished": "2023-04-17", "url": "https://questionsmedicales.fr/article/37143768", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fsurg.2023.1131385" } }, { "@type": "ScholarlyArticle", "name": "Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomes.", "datePublished": "2023-04-07", "url": "https://questionsmedicales.fr/article/38554321", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4103/jcrt.jcrt_225_22" } }, { "@type": "ScholarlyArticle", "name": "The role of diffusion magnetic resonance imaging in determining tumor aggressiveness during preoperative surgical planning in early-stage endometrial cancer.", "datePublished": "2023-04-04", "url": "https://questionsmedicales.fr/article/37014376", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00117-023-01134-7" } }, { "@type": "ScholarlyArticle", "name": "Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study.", "datePublished": "2023-03-23", "url": "https://questionsmedicales.fr/article/36952375", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cam4.5791" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Lipides", "item": "https://questionsmedicales.fr/mesh/D008055" }, { "@type": "ListItem", "position": 3, "name": "Lipides membranaires", "item": "https://questionsmedicales.fr/mesh/D008563" }, { "@type": "ListItem", "position": 4, "name": "Stérols", "item": "https://questionsmedicales.fr/mesh/D013261" }, { "@type": "ListItem", "position": 5, "name": "Cholestérol", "item": "https://questionsmedicales.fr/mesh/D002784" }, { "@type": "ListItem", "position": 6, "name": "Oxystérols", "item": "https://questionsmedicales.fr/mesh/D000072376" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Oxystérols - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Oxystérols", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Oxystérols", "description": "Comment diagnostiquer une dysfonction liée aux oxystérols ?\nQuels tests sont utilisés pour mesurer les oxystérols ?\nLes symptômes peuvent-ils indiquer un excès d'oxystérols ?\nY a-t-il des biomarqueurs pour les oxystérols ?\nComment les oxystérols sont-ils liés aux maladies cardiovasculaires ?", "url": "https://questionsmedicales.fr/mesh/D000072376?mesh_terms=Early+Detection+of+Cancer&page=998#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Oxystérols", "description": "Quels sont les symptômes d'une accumulation d'oxystérols ?\nLes oxystérols peuvent-ils affecter le système nerveux ?\nY a-t-il des signes cutanés liés aux oxystérols ?\nComment les oxystérols influencent-ils le métabolisme ?\nPeut-on ressentir des douleurs musculaires avec des oxystérols élevés ?", "url": "https://questionsmedicales.fr/mesh/D000072376?mesh_terms=Early+Detection+of+Cancer&page=998#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Oxystérols", "description": "Comment prévenir les troubles liés aux oxystérols ?\nLe contrôle du poids aide-t-il à prévenir les problèmes d'oxystérols ?\nLes examens réguliers sont-ils importants pour les oxystérols ?\nL'exercice physique influence-t-il les niveaux d'oxystérols ?\nLes habitudes alimentaires peuvent-elles prévenir les troubles d'oxystérols ?", "url": "https://questionsmedicales.fr/mesh/D000072376?mesh_terms=Early+Detection+of+Cancer&page=998#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Oxystérols", "description": "Quels traitements existent pour les troubles liés aux oxystérols ?\nLes statines sont-elles efficaces contre les oxystérols ?\nY a-t-il des thérapies ciblées pour les oxystérols ?\nComment la diététique aide-t-elle à gérer les oxystérols ?\nLes suppléments peuvent-ils aider à réguler les oxystérols ?", "url": "https://questionsmedicales.fr/mesh/D000072376?mesh_terms=Early+Detection+of+Cancer&page=998#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Oxystérols", "description": "Quelles complications peuvent survenir avec des oxystérols élevés ?\nLes oxystérols sont-ils liés à des maladies hépatiques ?\nPeut-on développer un diabète avec des oxystérols anormaux ?\nLes troubles cognitifs sont-ils liés aux oxystérols ?\nLes oxystérols peuvent-ils affecter la santé osseuse ?", "url": "https://questionsmedicales.fr/mesh/D000072376?mesh_terms=Early+Detection+of+Cancer&page=998#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Oxystérols", "description": "Quels sont les facteurs de risque pour les troubles d'oxystérols ?\nL'hérédité joue-t-elle un rôle dans les troubles d'oxystérols ?\nLe mode de vie sédentaire est-il un facteur de risque ?\nLe tabagisme influence-t-il les niveaux d'oxystérols ?\nLe stress peut-il affecter les niveaux d'oxystérols ?", "url": "https://questionsmedicales.fr/mesh/D000072376?mesh_terms=Early+Detection+of+Cancer&page=998#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction liée aux oxystérols ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins mesurant les niveaux d'oxystérols." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour mesurer les oxystérols ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses de sang spécifiques, comme la chromatographie, sont utilisées." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils indiquer un excès d'oxystérols ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la fatigue ou des troubles neurologiques peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs pour les oxystérols ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains oxystérols peuvent servir de biomarqueurs dans des pathologies spécifiques." } }, { "@type": "Question", "name": "Comment les oxystérols sont-ils liés aux maladies cardiovasculaires ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'oxystérols sont associés à un risque accru de maladies cardiovasculaires." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une accumulation d'oxystérols ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, douleurs abdominales et troubles neurologiques." } }, { "@type": "Question", "name": "Les oxystérols peuvent-ils affecter le système nerveux ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux peuvent entraîner des troubles neurologiques." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés liés aux oxystérols ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées ou des anomalies peuvent survenir en cas d'accumulation." } }, { "@type": "Question", "name": "Comment les oxystérols influencent-ils le métabolisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Ils régulent le métabolisme lipidique, affectant le stockage et l'utilisation des graisses." } }, { "@type": "Question", "name": "Peut-on ressentir des douleurs musculaires avec des oxystérols élevés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs musculaires peuvent être un symptôme d'une dysfonction lipidique." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés aux oxystérols ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine et un mode de vie actif sont essentiels pour la prévention." } }, { "@type": "Question", "name": "Le contrôle du poids aide-t-il à prévenir les problèmes d'oxystérols ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, maintenir un poids santé peut réduire le risque de troubles liés aux oxystérols." } }, { "@type": "Question", "name": "Les examens réguliers sont-ils importants pour les oxystérols ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des bilans de santé réguliers aident à détecter les anomalies précocement." } }, { "@type": "Question", "name": "L'exercice physique influence-t-il les niveaux d'oxystérols ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut aider à réguler les niveaux d'oxystérols dans le sang." } }, { "@type": "Question", "name": "Les habitudes alimentaires peuvent-elles prévenir les troubles d'oxystérols ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en fibres et faible en graisses saturées est bénéfique." } }, { "@type": "Question", "name": "Quels traitements existent pour les troubles liés aux oxystérols ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des modifications diététiques et des médicaments hypolipémiants." } }, { "@type": "Question", "name": "Les statines sont-elles efficaces contre les oxystérols ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les statines peuvent aider à réduire les niveaux d'oxystérols dans le sang." } }, { "@type": "Question", "name": "Y a-t-il des thérapies ciblées pour les oxystérols ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées sont en développement pour traiter les dysfonctionnements liés." } }, { "@type": "Question", "name": "Comment la diététique aide-t-elle à gérer les oxystérols ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut réduire les niveaux d'oxystérols et améliorer la santé." } }, { "@type": "Question", "name": "Les suppléments peuvent-ils aider à réguler les oxystérols ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments, comme les oméga-3, peuvent aider à équilibrer les lipides." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des oxystérols élevés ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des maladies cardiovasculaires et des troubles neurologiques." } }, { "@type": "Question", "name": "Les oxystérols sont-ils liés à des maladies hépatiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés peuvent contribuer à des maladies du foie et à la stéatose." } }, { "@type": "Question", "name": "Peut-on développer un diabète avec des oxystérols anormaux ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux d'oxystérols anormaux peuvent augmenter le risque de diabète." } }, { "@type": "Question", "name": "Les troubles cognitifs sont-ils liés aux oxystérols ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés peuvent être associés à des troubles cognitifs et à la démence." } }, { "@type": "Question", "name": "Les oxystérols peuvent-ils affecter la santé osseuse ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres peuvent influencer la santé osseuse et le risque de fractures." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles d'oxystérols ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'obésité, une alimentation riche en graisses et le diabète." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans les troubles d'oxystérols ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de dyslipidémies augmentent le risque." } }, { "@type": "Question", "name": "Le mode de vie sédentaire est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire contribue à des niveaux élevés d'oxystérols." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il les niveaux d'oxystérols ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut aggraver les dysfonctionnements lipidiques et les niveaux d'oxystérols." } }, { "@type": "Question", "name": "Le stress peut-il affecter les niveaux d'oxystérols ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber le métabolisme lipidique et augmenter les oxystérols." } } ] } ] }

Sources (10000 au total)

The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.

There are a paucity of data and a pressing need to evaluate response to neoadjuvant chemotherapy (NACT) and determine long-term outcomes in young Black women with early-stage breast cancer (EBC).... We analyzed data from 2196 Black and White women with EBC treated at the University of Chicago over the last 2 decades. Patients were divided into groups based on race and age at diagnosis: Black wome... Young Black women had the highest risk of recurrence, which was 22% higher than young White women (p = 0.434) and 76% higher than older Black women (p = 0.008). These age/racial differences in recurre... Black women with EBC had significantly worse outcomes compared to White women in our cohort study. There is an urgent need to understand the disparities in outcomes between Black and White breast canc...

Influence of adverse effects of neoadjuvant chemoradiotherapy on the prognosis of patients with early-stage esophageal cancer (cT1b-cT2N0M0) based on the SEER database.

To analyze the prognostic impact of neoadjuvant chemoradiotherapy (NCRT) on early-stage (cT1b-cT2N0M0) esophageal cancer (ESCA) and construct a prognostic nomogram for these patients.... We extracted the clinical data about patients diagnosed with early-stage esophageal cancer from the 2004-2015 period of the Surveillance, Epidemiology, and End Results (SEER) database. We applied the ... Among patients who met the inclusion criteria, patients in the NCRT plus esophagectomy (ES) group had a poorer prognosis for overall survival (OS) and esophageal cancer-specific survival (ECSS) than p... Patients with early-stage ESCA (cT1b-cT2) did not benefit from NCRT, and we established a prognostic nomogram to provide clinical decision aid for the treatment of patients with early-stage ESCA....

Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomes.

There is limited data with regard to the use of modified 5-fluoroural-leucovorin-irinotecan-oxaliplatin (mFOLFIRINOX) in terms of tolerance and enabling total mesorectal excision (TME) of locally adva... Patients with LARC from January 2018 to December 2020 receiving mFOLFIRINOX post NACTRT/SCRT to facilitate TME were evaluated. The primary endpoint was assessment of grade 3 and grade 4 treatment rela... Forty-seven patients were evaluated with a median age of 33 years (Range:18-59), 45% T4b status, 96% radiological circumferential margin (CRM) involved (79% CRM positive post NACTRT/SCRT), 43% extramu... Locally advanced rectal cancers with high-risk characteristics are a niche group of cancers with less-than-optimal outcomes post standard neoadjuvant strategies. mFOLFIRINOX appears to be well tolerat...

The role of diffusion magnetic resonance imaging in determining tumor aggressiveness during preoperative surgical planning in early-stage endometrial cancer.

The present study aimed to evaluate the relationship between tumor volume and apparent diffusion coefficient (ADC) in preoperative magnetic resonance imaging and deep myometrial invasion, tumor grade,... The study included 73 patients diagnosed with early-stage endometrial cancer based on histopathological examination between May 2014 and July 2019. Receiver operating characteristic (ROC) curve analys... The areas under the ROC curves (AUCs) of ADC and tumor volume in predicting LVI, DMI, and high tumor grade were significantly greater than those for superficial myometrial invasion and low-grade tumor... In the absence of pathological pelvic lymph nodes in early-stage endometrial cancer, tumor volume in DWI sequences determines the active tumor load and tumor aggressiveness. Furthermore, a low ADC ind...

Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study.

Although early diagnosis and surgical resection of the tumor have been shown to be the most important predictors of lung cancer survival, long-term survival for surgically-resected early-stage lung ca... In this prospective study we aimed to investigate the survival and prognostic factors of surgically-resected early-stage non-small cell lung cancer (NSCLC) in Central and Eastern Europe.... We recruited 2052 patients with stage I-IIIA NSCLC from 9 centers in Russia, Poland, Serbia, Czech Republic, and Romania, between 2007-2016 and followed them annually through 2020.... During follow-up, there were 1121 deaths (including 730 cancer-specific deaths). Median survival time was 4.9 years, and the 5-year overall survival was 49.5%. In the multivariable model, mortality wa... This study shows that the 5-year survival rate of surgically-resected stage I-IIIA NSCLC is still around 50% in Central and Eastern Europe. In addition to non-modifiable prognostic factors, lifetime p...

Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment.

Currently, targeting immune checkpoint molecules holds great promise for triple-negative breast cancer (TNBC). However, the expression landscape of immune checkpoint genes (ICGs) in TNBC remains large... Herein, we systematically investigated the ICGs expression patterns in 422 TNBC samples. We evaluated the ICGs molecular typing based on the ICGs expression profile and explored the associations betwe... Two ICGs clusters and two ICGs-related gene clusters were determined, which were involved in different survival outcomes, biological roles and infiltration levels of immune cells. We established a qua... Collectively, dissecting the ICGs expression patterns not only provides a new insight into TNBC subtypes but also deepens the understanding of ICGs in the tumor immune microenvironment....

Meta-analysis of laparoscopic radical hysterectomy, excluding robotic assisted versus open radical hysterectomy for early stage cervical cancer.

Recent evidence has shown an increase in recurrence and a decrease in overall survival in patients treated with laparoscopic radical hysterectomy (LRH) and robotic assisted radical hysterectomy (RRH) ...

Initial Experience With Trans-anal Minimally Invasive Surgery (TAMIS) for Rectal Polyps and Early Colorectal Cancers at Cumberland Infirmary, Carlisle.

Bowel cancer is the fourth most common type of cancer in the United Kingdom in 2019. Total mesorectal excision is the standard procedure for the removal of rectal tumors, however, it comes with seriou... During a five-year period, 42 patients underwent TAMIS at Cumberland Infirmary. The primary indication for TAMIS was distal rectal lesions, large rectal polyps up to 120 mm, and early rectal cancer (T... Our findings suggest that TAMIS produces positive results. The size of the lesions removed, and the effect of an early learning curve are reflected in the rate of specimen fragmentation and polyp recu...